

Hyloris Pharmaceuticals SA

Limited liability company (*société anonyme/naamloze vennootschap*)
Boulevard Patience & Beaujonc 3/1
4000 Liège
Belgium
Register of legal entities: 0674.494.151 (Liège, Liège Division)

(the “**Company**”)

MINUTES OF THE ORDINARY GENERAL MEETING OF 30 September 2024

On Monday, 30th of September 2024 at 10:00 (Central European Summer Time), an ordinary general meeting of shareholders (the “**Meeting**”) is held at Boulevard Patience & Beaujonc 3/1, 4000 Liège, Belgium.

OPENING OF THE MEETING

For this year's Meeting, the Company invites all participants to exercise their rights in one of the following manners:

1. Vote by letter ahead of the Meeting; or
2. Be represented by proxy at the Meeting; or
3. Participate electronically during the Meeting via Teams; or
4. Attend the Meeting physically.

Composition of the Bureau

The Meeting is opened at 10:00 under the chairmanship of Mr. Stefan Yee (the **Chairman**).

The Chairman appoints Mr. Koenraad Van der Elst as secretary of the Meeting (the **Secretary**).

The Chairman proposes not to appoint tellers to count the votes. The Meeting unanimously agrees on this point.

The Chairman, M. Thomas Jacobsen (CFO) and the Secretary together form the bureau (the **Bureau**).

Working language

The Chairman notes that, in accordance with applicable law, French is the official working language for the Meeting. The Chairman notes that a translation in English of the minutes of this Meeting will be provided.

CONVOCATION OF THE MEETING

The notice convening this Meeting as provided for in the Belgian companies and associations code (the **Belgian Companies and Associations Code**), has been published in:

- the Belgian Official Gazette on 28 August 2024;
- the Company's website on 28 August 2024

Proof of the publications are submitted to the Bureau. The proof will be kept in the files of the Company, together with the minutes of this Meeting.

The notices convening the Meeting have also been sent on August 27, 2024 to the registered shareholders, the warrant holders, the directors and the statutory auditor KPMG Bedrijfsrevisoren, represented by Mr. Legein.

Proof of the convening notice is being submitted to the Bureau. The proof will be kept in the files of the Company together with the minutes of this Meeting.

In addition, as from 28 August 2022, the following documentation has been made available to the shareholders and to the public issued by the Company on the Company's website:

- the convening notice;
- a proxy form;
- a vote by letter form;
- the annual report 2023
- the Remuneration Report 2023
- the 2023 statutory annual accounts (French only);
- report of the Board of Directors on the annual accounts for the year ended 31 December 2023;
- statutory auditor's report on the consolidated accounts for the year ended 31 December 2023;
- statutory auditor's report on the annual accounts for the year ended 31 December 2023;

Proof of the publication of the convening notices, proof of the convening notice and proof of publication of the documents mentioned in the list above will be kept in the files of the Company together with the minutes of this Meeting.

ATTENDANCE LIST

The registration date of the Meeting was Tuesday, 24th of September 2023 at midnight (24:00 (Central European Summer Time)). In accordance with the applicable legislation, only persons holding shares issued by the Company at the aforementioned registration date shall be entitled to participate in the Meeting and are listed in the attendance list attached as Annex 1.

In this respect, an attendance list has been prepared indicating (i) the identity of the shareholders which participate to the Meeting, (ii) the domicile or registered office of such shareholders, (iii) if applicable, the identity of the proxy holder of such shareholders, and (iv) the number of shares with which such shareholders are participating in the voting.

A separate list has been prepared for the shareholders that have validly submitted their votes by letter in accordance with the Belgian Companies and associations code and the articles of association of the Company.

Further, the Company has not received any request, in accordance with the Belgian Companies and Associations Code, from shareholders who, alone or jointly, represent at least three (3) % of the capital, to include additional items on the agenda of the Meeting and/or to propose draft resolutions concerning items that have been or should have been included on the agenda.

The Company's capital amounts to 140.001,87 EUR and is represented by 28.000.374 shares, without nominal value, each representing the same fraction of the Company's capital.

Based on the aforementioned attendance list and the verification of the admission to the Meeting, it appears that 16.632.782 shares in total or 59,40 % of the outstanding and existing shares are present or represented at the Meeting.

The Chairman notes that the directors of the Company, other than Mr. Van Rompay, Mr. Jacobsen and Mr. Yee, were invited but did not participate to the Meeting:

Finally, the Chairman notes that the statutory auditor of the Company, KPMG Bedrijfsrevisoren, represented by Mr. Tanguy Legein, also participates to the Meeting.

QUORUM AND VOTING

In accordance with article 25/1 of the law of 2 May 2007 on the on the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market, and the articles of associations of the Company, no person can participate to an ordinary general meeting for more voting rights than attached to the shares with respect to which such person has filed with the Company a notification at least twenty (20) days prior to the date of the ordinary general meeting. The relevant thresholds for a notice are three (3) %, five (5) %, seven and a half (7.5) %, ten (10) %, fifteen (15) %, twenty (20) % and any further multiple of five (5) % of the outstanding voting rights. For all shareholders voting by letter or voting by proxy, it is established that they can participate with all the shares they have deposited.

There is no quorum or majority requirement for deliberating and voting on the Meeting's agenda items

below. Subject to applicable law, each share is entitled to one vote. The resolutions proposed in the agenda will be passed if a simple majority of the votes validly cast approves it.

In accordance with Article 7:135 of the Belgian Companies and Associations Code, the holders of profit-sharing certificates, convertible bonds, warrants or certificates issued with the cooperation of the Company are entitled to participate in the Meeting and may cast an advisory vote.

VALIDITY OF THE MEETING

The aforementioned statements of the Chairman are verified and approved by the Meeting. Subsequently, the Meeting determines and confirms that it has been validly convened and is validly constituted.

AGENDA AND RESOLUTIONS

AGENDA

The Chairman elaborates upon the Meeting's agenda items:

1. Take cognizance of the Board of Directors' report for the financial year ending on the 31st of December 2023.
2. Take cognizance of the statutory auditor's report for the financial year ending on the 31st of December 2023.
3. Approve the annual accounts for the financial year ending on the 31st of December 2023 and approve profit-and-loss allocation.
4. Take cognizance of the Board of Directors' and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2023.
5. Take cognizance of the consolidated annual accounts for the financial year ending on the 31st of December 2023.
6. Take cognizance of the end of the mandate of Pieter Jan SRL/BV, permanently represented by Mr. Chris Buyse.
7. Grant discharge to the directors.
8. Grant discharge to the statutory auditor.
9. Approve the (re)appointment of directors.
10. Vote (advisory vote) on the remuneration report for the financial year ending on the 31st of December 2023.
11. Approve the remuneration policy.
12. Grant power of attorney for the performance of formalities.

QUESTIONS

Every shareholder and warrant holder had the right to ask questions to the Board of Directors and the statutory auditor in relation to the items on the agenda of the Meeting.

The following questions were submitted prior to the Meeting:

- People are leaving regularly and the 2 open positions on your website stay open: what is the hiring strategy (open positions, CFO, CLO,...) and are we sufficiently staffed to support the growth without new employees?:
- Promise to expand to 30 assets by 2024, average 4 new candidates per year: there are symptoms of systematic overpromise and underdeliver. Will communication improve in 2024 and 2025?
- AltaThera litigation: what is the latest status. Will AltaThera generate sales in the future? Will the incurred costs be compensated?

The Chairman proposes to respond now to the questions that were submitted prior to the Meeting.

- Regarding the 1st question on the hiring strategy: Mr. Stijn Van Rompay explained that only a few employees have left the company in recent years, suggesting that turnover is relatively low. However, he acknowledges that finding individuals with the right skills remains challenging, especially given that the company prefers not to match the remuneration levels of larger pharmaceutical firms. Despite this, the company has consistently been able to attract qualified talent. The search for a new CFO and CLO is currently underway.
- Regarding the 2nd question on the expansion of the product range: Mr. Stijn Van Rompay stated that the company is increasingly focusing on 'repurposing' rather than 'reformulation.' These are more expensive, and time consuming but can have a greater financial reward. The company is aiming to add products to its portfolio in the next months and will continue to explore new opportunities. Additionally, several projects are being developed, which are only communicated to the market once they reach a certain level of maturity. The company is also committed to further improving its communication efforts.
- With regard to question 3e concerning the AltaThera dispute: Mr. Van Rompay stated that AltaThera will continue to sell Sotalol IV, and that Hyloris will continue to receive royalties. The costs incurred in the litigation have an (beneficial) impact on the royalties that become payable to API, the U.S. development partner.

RESOLUTIONS

Before opening the votes, the President recalls that with the Auditor's agreement, the bureau was exempted from reading the reports provided for on the agenda, these having been available to each of the shareholders who were thus able to read these documents before the meeting.

The Meeting proceeds to the deliberation of the Meeting's agenda items:

1. Take cognizance of the Board of Directors' report for the financial year ending on the 31st of December 2023

Proposed Resolution

The Board of Directors affirms that this agenda item does not require a resolution.

Resolution:

The Meeting takes note of the Board of Directors' report for the financial year ending on the 31st of December 2023.

2. Take cognizance of the statutory auditor's report for the financial year ending on the 31st of December 2023

Proposed Resolution

The Board of Directors affirms that this agenda item does not require a resolution.

Resolution:

The Meeting takes note of the statutory auditor's report for the financial year ending on the 31st of December 2023.

3. Approve the annual accounts for the financial year ending on the 31st of December 2023 and approve the profit-and-loss allocation

Proposed Resolution

It is proposed to approve the annual accounts for the financial year ending on the 31st of December 2023 and the profit-and-loss allocation as proposed by the Board of Directors. The profit-and-loss allocation is set out as follows:

Loss of financial year 2023	EUR – 3.402.000
Loss carried forward from the previous financial year	EUR – 15.504.000
Loss to carry forward	EUR – 18.906.000

Resolution:

The Meeting resolves to approve the annual accounts for the financial year ending on the 31st of December 2023 and the profit-and-loss allocation as proposed by the Board of Directors.

The profit-and-loss allocation is set out as follows:

Loss of financial year 2023	EUR – 3.402.000
-----------------------------	-----------------

Loss carried forward from the previous financial year	EUR – 15.504.000
Loss to carry forward	EUR – 18.906.000

This resolution is passed as follows:

FOR	AGAINST	ABSTAIN
16.630.162	2120	500

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

4. Take cognizance of the Board of Directors and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2023

Proposed Resolution

The Board of Directors affirms that this agenda item does not require a resolution.

Resolution:

The Meeting takes note of the Board of Directors and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2023.

5. Take cognizance of the consolidated annual accounts for the financial year ending on the 31st of December 2023

Proposed Resolution

The Board of Directors affirms that this agenda item does not require a resolution.

Resolution:

The Meeting takes note of the consolidated annual accounts for the financial year ending on the 31st of December 2023.

6. Take cognizance of the end of the mandate of Pieter Jan SRL/BV, permanently represented by Mr. Chris Buyse

Proposed Resolution

It is proposed to take cognizance of the end of, and, as far as necessary, to accept, the dismissal of Pieter Jan SRL/BV, permanently represented by Mr. Chris Buyse, with effect as from the close of the Annual Shareholders' Meeting that will vote on the annual accounts for the financial year ending on the 31st of December 2023..

Resolution:

The Meeting takes note of the end of, and, as far as necessary, accepts, the dismissal of Pieter Jan SRL/BV, permanently represented by Mr. Chris Buyse, with effect as from the close of the Annual Shareholders' Meeting that will vote on the annual accounts for the financial year ending on the 31st of December 2023.

This resolution is passed as follows:

FOR	AGAINST	ABSTAIN
16.632.782	0	0

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

7. Grant discharge to the Directors

Proposed Resolution

It is proposed that discharge be granted to the following directors in respect of their mandate for the financial year ending on the 31st of December 2023, including the convening of the Annual Shareholders' Meeting as well as the submission, publication and filing of the (consolidated) annual accounts and the annual report and audit report on the (consolidated) annual accounts in derogation of the applicable legal and statutory provisions (relating to the convening, formalities, deadlines, the availability of certain documents on specific dates and the dates on which the meeting is held):

- I. SVR Management SRL, represented by Mr. Stijn van Rompay,
- II. Jacobsen Management SRL, represented by Mr. Thomas Jacobsen,
- III. Van Rompay Management SRL, represented by Mr. Leon Van Rompay,
- IV. Noshag Partners SRL, represented by Mr. Marc Foidart,
- V. Mr. Stefan Yee,
- VI. Mrs. Caroline Myers,
- VII. Mr. James Gale, and
- VIII. Pieter Jan SRL, permanently represented by Mr. Chris Buyse.

Resolution:

The Meeting resolves to discharge the following directors in respect of their mandate for the financial year ending on the 31st of December 2023, including the convening of the Annual Shareholders' Meeting as well as the submission, publication and filing of the (consolidated) annual accounts and the annual report and audit report on the (consolidated) annual accounts in derogation of the applicable legal and statutory provisions (relating to the convening, formalities, deadlines, the availability of certain documents on specific dates and the dates on which the meeting is held):

- I. SVR Management SRL, represented by Mr. Stijn van Rompay,
- II. Jacobsen Management SRL, represented by Mr. Thomas Jacobsen,

- III. Van Rompay Management SRL, represented by Mr. Leon Van Rompay,
- IV. Noshag Partners SRL, represented by Mr. Marc Foidart,
- V. Mr. Stefan Yee,
- VI. Mrs. Caroline Myers,
- VII. Mr. James Gale, and
- VIII. Pienter Jan SRL, permanently represented by Mr. Chris Buyse.

This resolution is passed as follows:

For SVR Management SRL, represented by M. Stijn van Rompay,

FOR	AGAINST	ABSTAIN
16.630.162	2.620	0

For Jacobsen Management SRL, represented by M. Thomas Jacobsen,

FOR	AGAINST	ABSTAIN
16.630.162	1.832	788

For Van Rompay Management SRL, represented by M. Leon Van Rompay,

FOR	AGAINST	ABSTAIN
16.630.162	2.620	0

For Noshag Partners SRL, represented by M. Marc Foidart,

FOR	AGAINST	ABSTAIN
16.632.662	2.120	0

For M. Stefan Yee,

FOR	AGAINST	ABSTAIN
16.632.662	2.120	0

Mr Ms Caroline Myers,

FOR	AGAINST	ABSTAIN
16.632.662	2.120	0

For M. James Gale

FOR	AGAINST	ABSTAIN
16.632.662	2.120	0

For Pienter Jan SRL, represented by M. Chris Bruyse.

FOR	AGAINST	ABSTAIN
4.667.493	11.464.789	500.500

No discharge was given to Pienter Jan BV.

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

8. Grant discharge to the statutory auditor

Proposed Resolution

It is proposed that discharge be granted to the statutory auditor, in respect of its duties for the financial year ending on the 31st of December 2023.

Resolution:

The Meeting resolves to grant discharge to the statutory auditor, in respect of its duties for the financial year ending on the 31st of December 2023.

This resolution is passed as follows:

FOR	AGAINST	ABSTAIN
4.667.493	2.120	11.963.169

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

9. Approve the (re)appointment of directors

Proposed Resolution

It is proposed to (re)appoint:

- (i) SVR Management SRL, represented by Mr. Stijn Van Rompay, as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (ii) Jacobsen Management SRL, represented by Mr. Thomas Jacobsen, as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (iii) Van Rompay Management SRL, represented by Mr. Leon Van Rompay, as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (iv) Mr. Stefan Yee as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (v) Mrs. Revital Rattenbach as independent director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (vi) Mr. Marc Foidart as independent director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company, and
- (vii) Mr. Vincent Van Dessel as independent director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company.

Resolution:

The Meeting resolves to (re)appoint:

- (i) SVR Management SRL, represented by Mr. Stijn Van Rompay, as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (ii) Jacobsen Management SRL, represented by Mr. Thomas Jacobsen, as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (iii) Van Rompay Management SRL, represented by Mr. Leon Van Rompay, as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,
- (iv) Mr. Stefan Yee as director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,

(v) Mrs. Revital Rattenbach as independent director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company,

(vi) Mr. Marc Foidart as independent director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company, and

(vii) Mr. Vincent Van Dessel as independent director for a term of 4 years, until the close of the annual general meeting to be held in 2028, and remunerated according to the Remuneration Policy of the Company.

This resolution is passed as follows:

For SVR Management SRL, represented by M. Stijn van Rompay,

FOR	AGAINST	ABSTAIN
16.630.162	2.620	0

For Jacobsen Management SRL, represented by M. Thomas Jacobsen,

FOR	AGAINST	ABSTAIN
16.630.282	0	500

For Van Rompay Management SRL, represented by M. Leon Van Rompay,

FOR	AGAINST	ABSTAIN
16.630.282	500	0

For M. Stefan Yee,

FOR	AGAINST	ABSTAIN
16.631.994	288	500

Mr Ms Revital Rattenbach

FOR	AGAINST	ABSTAIN
16.632.282	0	500



For M. Marc Foidart

FOR	AGAINST	ABSTAIN
16.632.782	0	0

For M. Vincent Van Dessel

FOR	AGAINST	ABSTAIN
16.632.782	0	0

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

10. Vote (advisory vote) on the remuneration report for the financial year ending on the 31st of December 2022

Proposed Resolution

It is proposed to approve the remuneration report for the financial year ending on the 31st of December 2023, as elaborated in the annual report in the subsection Corporate Governance – Remuneration Report (p. 62 and following), be approved. The 2023 annual report is available on the Company's website at <https://hyloris.com/second-general-assembly-2024/>.

Resolution:

The Meeting resolves to approve the remuneration report for the financial year ending on the 31st of December 2023, as elaborated in the annual report in the subsection Corporate Governance – Remuneration Report (p. 62 and following), be approved. The 2023 annual report is available on the Company's website at <https://hyloris.com/second-general-assembly-2024/>.

This resolution is passed as follows:

FOR	AGAINST	ABSTAIN
16.630.450	1.832	500

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

11. Approve the remuneration policy.

Proposed Resolution

It is proposed to approve the amended remuneration policy in accordance with article 7:89/1 of the BCCA.

Resolution:

The Meeting resolves to approve the amended remuneration policy in accordance with article 7:89/1 of the BCCA.

This resolution is passed as follows:

FOR	AGAINST	ABSTAIN
16.630.450	1.832	500

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.

12. Grant power of attorney for the performance of formalities.

Proposed Resolution

It is proposed that special powers be granted to Mr. Stefan Yee, Chairman of the Board of Directors of the Company, Erwin Destuyver, Michiel Stuyts and Marion Baine (attorneys with Eubelius BV/SRL) and Silke De Greef (paralegal assistant with Eubelius BV/SRL), as well as, more generally, all attorneys and paralegal assistants of Eubelius BV/SRL, to allow them to act individually, and with full power of substitution and sub-delegation, to perform in the name and on behalf of the Company all formalities pertaining to the publication obligations imposed by law regarding the resolutions adopted at the Annual Shareholders' Meeting and, more particularly, to publish an excerpt of these minutes in the Annexes to the Belgian Official Gazette and, generally, to perform all steps at the Clerk's office of the Court of Enterprises and everything necessary for these purposes. To the extent permitted by law, the company waives any liability claim against the attorney(s)-in-fact (as well as the substitutes and subdelegates) and undertakes to indemnify them for any damage they may incur because of any act carried out in relation to this power of attorney.

Resolution:

The Meeting resolves to grants special powers to Mr. Stefan Yee, Chairman of the Board of Directors of the Company, Erwin Destuyver, Michiel Stuyts and Marion Baine (attorneys with Eubelius BV/SRL) and Silke De Greef (paralegal assistant with Eubelius BV/SRL), as well as, more generally, all attorneys and paralegal assistants of Eubelius BV/SRL, to allow them to act individually, and with full power of substitution and sub-delegation, to perform in the name and on behalf of the Company all formalities pertaining to the publication obligations imposed by

law regarding the resolutions adopted at the Annual Shareholders' Meeting and, more particularly, to publish an excerpt of these minutes in the Annexes to the Belgian Official Gazette and, generally, to perform all steps at the Clerk's office of the Court of Enterprises and everything necessary for these purposes. To the extent permitted by law, the company waives any liability claim against the attorney(s)-in-fact (as well as the substitutes and subdelegates) and undertakes to indemnify them for any damage they may incur because of any act carried out in relation to this power of attorney.

This resolution is passed as follows:

FOR	AGAINST	ABSTAIN
16.632.282	0	500

16.632.782 valid votes have been registered for shares, which represents 59,40 % of the capital of the Company.


As no further agenda items need to be dealt with and no one asks to take the floor, the Chairman closes the Meeting at 11:35.

These minutes are signed by the Bureau.

Signed by:




Stefan Yee
Chairman



Koenraad Van der Elst
Secretary

i.o.



Thomas Jacobsen

Annex 1 : Attendance lists

Shareholder/Warrant holder	Address	PC	City	# Shares (in register/registered)
Stijn Van Rompay	Luchthavenlaan	3140	Keerbergen	7.743.067
Nati Ortiz Gordo	Mereldreef 55	3140	Keerbergen	320.000
Thomas Jacobsen	Beekstraat 73	1980	Zemst	3.857.838
Pieter Van Rompay	Mereldreef 55	3140	Keerbergen	1.041.744
Lieve Van Rompay	Papenakker 17	9070	Heusden	400.000
Nick Reunbroek	Papenakker 17	9070	Heusden	1.537.266
Saffelberg Investments NV	Oplombeekstraat 6	1755	Gooik	721.818
AMV 123 (Michel Delloye)				30.000
Tesveil BM	Schoonhovendreef 1	3200	Aarschot	330.578
Marc Corluy	Bredabaan 879	2930	Brasschaat	149.592
Maurizio Passanisi				94.524
Robert Taub	Avenue des Croix de Guerre 149/13	1120	Bruxelles	361.764
Kurt De Herdt	Zwaluwenlaan 3	1780	Wemmel	28.131
Robbe De Herdt	Zwaluwenlaan 3	1780	Wemmel	2.360
Pascale Bauwens	Zwaluwenlaan 3	1780	Wemmel	7.250
Amber De Herdt	Zwaluwenlaan 3	1780	Wemmel	2.360
André Bauwens	Zwaluwenlaan 1	1780	Wemmel	1.870
Euroclear Bank NV	1 Bd. Du Roi Albert II	1210	Bruxelles	500
Citibank Europe Plc	1 North Wall Quay	1	Dublin	1.832
BNP Paribas	Warandeborg 3	1000	Brussel	288

16.632.782

59,40%
